BioGaia AB: Interim Management Statement – January - March 2023
FIRST QUARTER 2023 Figures in parentheses refer to the corresponding period last year, unless otherwise specified. · Net sales amounted to SEK 365.8 million (283.9), an increase of SEK 82.0 million, or 29% (excluding foreign exchange effects, 19%). · Net sales in the Paediatrics segment amounted to SEK 306.0 million (222.5), an increase of 37% (excluding foreign exchange effects, 27%). · Net sales in the Adult Health segment amounted to SEK 56.6 million (60.8), a decrease of 7% (excluding foreign exchange effects a decrease of 14%). · Operating expenses amounted to SEK 114.